Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Q3 2025 value amounting to $301000.0.

  • Vanda Pharmaceuticals' Depreciation & Amortization (CF) rose 3935.19% to $301000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 2586.0%. This contributed to the annual value of $900000.0 for FY2024, which is 217.39% down from last year.
  • As of Q3 2025, Vanda Pharmaceuticals' Depreciation & Amortization (CF) stood at $301000.0, which was up 3935.19% from $267000.0 recorded in Q2 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Depreciation & Amortization (CF) ranged from a high of $374000.0 in Q4 2021 and a low of $200000.0 during Q3 2023
  • Over the past 5 years, Vanda Pharmaceuticals' median Depreciation & Amortization (CF) value was $284000.0 (recorded in 2022), while the average stood at $275578.9.
  • In the last 5 years, Vanda Pharmaceuticals' Depreciation & Amortization (CF) plummeted by 3311.04% in 2023 and then soared by 3935.19% in 2025.
  • Quarter analysis of 5 years shows Vanda Pharmaceuticals' Depreciation & Amortization (CF) stood at $374000.0 in 2021, then decreased by 24.06% to $284000.0 in 2022, then fell by 27.82% to $205000.0 in 2023, then grew by 27.8% to $262000.0 in 2024, then rose by 14.89% to $301000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $301000.0 for Q3 2025, versus $267000.0 for Q2 2025 and $231000.0 for Q1 2025.